Evidence map›Paper›PMID 28935758›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2017

Scavenger Receptor CD36 Directs Nonclassical Monocyte Patrolling Along the Endothelium During Early Atherogenesis.

Paola M Marcovecchio, Graham D Thomas, Zbigniew Mikulski, Erik Ehinger, Karin A L Mueller, Amy Blatchley, Runpei Wu, Yury I Miller, Anh Tram Nguyen, Angela M Taylor and 3 more

Open access · bronzeAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 3 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Endothelial Metabolic Reprogramming Links Diabetes to Atherosclerosis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  7. Article
  8. Impaired CAMK4 Activity Limits Atherosclerosis and Reprograms Myelopoiesis.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The role of immune cells in different stages of atherosclerosis.International journal of medical sciences · 2024
    Review
  16. Lymphatic vasculature in ovarian cancer.Biochimica et biophysica acta. Reviews on cancer · 2023
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Paola M MarcovecchioFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Graham D ThomasFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Zbigniew MikulskiFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Erik EhingerFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Karin A L MuellerFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Amy BlatchleyFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Runpei WuFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Yury I MillerFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Anh Tram NguyenFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Angela M TaylorFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Coleen A McNamaraFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Klaus LeyFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.).
Catherine C HedrickFrom the Department of Medicine, University of California San Diego School of Medicine, La Jolla (P.M.M., Y.I.M.); Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (P.M.M., G.D.T., Z.M., E.E., K.A.L.M., A.B., R.W., K.L., C.C.H.); Department of Cardiology and Circulatory Diseases, Internal Medicine Clinic III, Eberhard Karls University Tübingen, Germany (K.A.L.M.); and Robert M. Berne Cardiovascular Research Center, Division of Cardiology, University of Virginia, Charlottesville (A.T.N., A.M.T., C.A.M.). hedrick@lji.org.
University of California, San Diego · US

Funding

ROLE OF LIPOXYGENASES IN ATHEROGENESIS IN DIABETES MELLITUSP01HL055798 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HEDRICK, CATHERINE C · 1995 to 2016
$28.4M
Project 4: APOB-specific CD4 and CD8 T cells exacerbate atherosclerosisP01HL136275 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Catherine C Hedrick · 2017 to 2026
$25.5M
Myeloid cell interactions with T cells in atherosclerosisR01HL115232 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI LEY, KLAUS F. · 2012 to 2018
$3.2M
Transcriptional Control of Monocyte DevelopmentR01HL134236 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C · 2016 to 2019
$2.5M
Nuclear Receptors in Myeloid Development, Inflammation, and AtherosclerosisR01HL118765 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C · 2013 to 2016
$2.2M
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514k
In vivo investigation of non-classical monocyte patrolling mechanismF31HL132538 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MARCOVECCHIO, PAOLA · 2016 to 2018
$98k
NHLBI NIH HHS F31 HL132538NHLBI NIH HHS P01 HL055798NHLBI NIH HHS P01 HL136275NHLBI NIH HHS R01 HL115232NHLBI NIH HHS R01 HL118765NHLBI NIH HHS R01 HL134236
6 · The paper itself

Abstract

objectiveNonclassical monocytes (NCM) function to maintain vascular homeostasis by crawling or patrolling along the vessel wall. This subset of monocytes responds to viruses, tumor cells, and other pathogens to aid in protection of the host. In this study, we wished to determine how early atherogenesis impacts NCM patrolling in the vasculature. APPROACH AND

resultsTo study the role of NCM in early atherogenesis, we quantified the patrolling behaviors of NCM in ApoE

conclusionsOur studies show a novel pathway for induction of NCM patrolling along the vascular wall during early atherogenesis. Mice fed a Western diet showed increased NCM patrolling activity with a concurrent increase in SFK phosphorylation. This patrolling activity was lost in the absence of either CD36 or DAP12. These data suggest that NCM function in an atheroprotective manner through sensing and responding to oxidized lipoprotein moieties via scavenger receptor engagement during early atherogenesis.

Indexed as

Leukocyte RollingActin CytoskeletonAdaptor Proteins, Signal TransducingAnimalsApolipoproteins EAtherosclerosisCD36 AntigensDiet, WesternDisease Models, AnimalEndothelial CellsEndothelium, VascularFemoral ArteryGenetic Predisposition to DiseaseHumansIntravital MicroscopyLipoproteins, LDLAdaptor Proteins, Signal TransducingApolipoproteins ECD36 AntigensLipoproteins, LDLoxidized low density lipoproteinsrc-Family KinasesTyrobp protein, mouseatherosclerosishumansmicemonocytesphosphorylation

Identifiers

PMID28935758
PMCPMC5930003
OpenAlexW2759198029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.